On March 5, Amgen registered 2 items on the Clinicaltrials website.Maridebart Cafraglutide（MariTide）Used forObesityPhase III Clinical Trial（MARITIME-1 andMARITIME-2). Public information shows that this is the drugFirst LaunchPhase III Clinical Trial.
Screenshot source:Clinicaltrials Website
MARITIME-1（NCT06858839) isA Phase III randomized, double-blind, placebo-controlled study,Proposed enrollment of 3,501 people,Aim to evaluate Maridebart Cafraglutide forObesity or overweight without type 2 diabetesEfficacy, safety, and tolerability in adult patients.MARITIME-2（NCT06858878）A Phase III randomized, double-blind, placebo-controlled study,Proposed inclusion999 subjects,Aim to evaluate Maridebart Cafraglutide forType 2 Diabetes with Obesity or OverweightEfficacy, Safety, and Tolerability in Adult Patients.Maridebart Cafraglutide It was developed by Amgen.Subcutaneous Injection of GLP-1R Agonist/GIPR Antagonist. Recently,The international top journal Nature published an article introducing the next generation of weight loss drugs currently under development, including Amgen'sMaridebart Cafraglutide。
Screenshot source:Corporate Website
In 2024, Amgen announcedPhase II, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study（NCT05669599）The positive results. This study aims to evaluateMariTide For overweight or obese adult subjects(Regardless of whether or not they have type 2 diabetes)Efficacy, safety, and tolerability.The primary endpoint isPercentage Change in Body Weight from Baseline to Week 52。
Data show,The non-Type 2 diabetes cohort included 465 participants, and after 52 weeks of treatment, thesePatientAverage weight loss was 20%, and no weight loss plateau has appeared,TriglyceridesReduced by 19%。
Screenshot source:Corporate Website
A total of 127 individuals were enrolled in the Type 2 diabetes cohort, and after 52 weeks of treatment, these patientsAverageWeight loss 17%，Glycated Hemoglobin（HbA1c）Decreased by 2.2%, triglycerides decreased by 28%。
Screenshot source:Corporate Website
In terms of safety, the most common adverse events were gastrointestinal-related, including nausea, vomiting, and constipation, and takingMariTide is not related to changes in bone density.Compared with existing weight-loss star drugs(Semaglutide and Tirzepatide)In comparison,Maridebart CafraglutideThe dosing frequency is lower, allowingOnce a month or even longer intervals between doses。
Cover Source: Corporate LogoDisclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.PR Article Coordination: WeChat insightxbSubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
